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An Alternative Analysis for Crossover Studies that Accounts for
Between-Group Disparities in Drug Response
Ton J. M. Cleophas
Departments of Medicine and Clinical Pharmacology, Merwede Hospital Dordrecht, Sliedrecht, The Netherlands
Summary: Background: In crossover clinical trials comparing completely different treatments, patients tend to fall
into different populations: those who respond better to treatment 1 and those who respond better to treatment 2.
The correlation between treatment response in such trials is negative. The current ANCOVA analysis for crossover
studies does not allow for correlations being negative, and is therefore not adequate for testing in this kind of trials.
Objective of study: To study whether matrix algebra provides a more appropriate approach for this purpose.
Results and conclusions: Using a mathematical model as well as hypothesized examples, it is demonstrated that
matrix algebra of 2 pairs of cells of the same order not only allows for negative correlations in a crossover design
but also provides enough power to test both the treatment and carryover effect.
Introduction
Following Grizzle and Brown (1, 2), many workers
(3—6) currently assume, for the analysis of crossover
studies, the following statistical model based on analysis
of covariance (ANCOVA):
Yijk = μ + ξϋ + nk + φι + 8ijk
where: yy-k is the response for the j subject in the i
sequence during the kth period
μ is the mean response
ξϊΐ is the effect of the jth subject in the 1th sequence
πk is the effect of the k* period
is the direct effect of the 1th treatment
is the carryover effect of the 1th treatment
Eijk is the independent error term
icjf + ai ifk = k'





i, yij2) = σ| / (of + σ*) = ρ
The merit of this ANCOVA approach is that it provides
a fairly straightforward way of carrying out an after-the-
fact statistical adjustment of the data, to equate concom-
itant variables or covariates. However, the problems of
this ANCOVA approach are:
1. it does not allow for correlations being negative, be-
cause σ| / (σ| + σ^) simply cannot be negative,
2. it fails to include a covariate related to differences in
the populations under study.
On the one hand, in a treatment comparison the new
treatment may be a slight modification of the standard
or be equivalent to it with the addition of a new compo-
nent. In this situation there is a positive correlation be-
tween the new and the standard treatment, i. e. treatment
1 will perform well when treatment 2 does so too. On
the other hand, in trials with completely different treat-
ments patients tend to fall into different populations:
those who respond to treatment 1 and those who respond
to treatment 2. Patients with angina pectoris unrespon-
sive to beta-blockers generally respond either to calcium
channel blockers or to nitroglycerines. Also hyperten-
sion, Raynaud's phenomenon, different types of cardiac
arrhythmias and chronic obstructive pulmonary disease
are known to be conditions where a non-response to a
particular compound is frequently associated with an ex-
cellent response to a completely different compound.
These are examples of situations in which a crossover
study is likely to give rise to a strong negative correla-
tion. This may even be so in spite of the general likeli-
hood in any crossover of a somewhat positive correla-
tion, because one subject is used for comparison of two
treatments. The mechanism of between-group disparities
has been well-recognized in clinical pharmacology; in
fact, this is the main reason that in treatment protocols
the principle of stepped care is currently being replaced
by individualized care (7). The recognition of between-
group disparities in drug response also implies that any
mathematical approach for crossover studies should al-
low for correlations being negative, and that the above
ANCOVA approach is not appropriate for that purpose.
A more appropriate approach would be the application
of basic matrix algebra in which 2 X 2 cells of the same
order can be added or subtracted in a cell by cell man-
ner. The current study investigates whether this ap-
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proach, unlike the ANCOVA, allows for correlations be-
ing negative, and provides adequate power to test both
treatment and carryover effects.
Statistical Model























Yijk = the response of the jth patient in the 1th group in
the k01 period. We assume that n2 = n2 = n.
Yi.k = Σ yijk/n
Also we assume:
1. that the samples have a normal distribution or a t-dis-
tribution,
2. that in a crossover without a carryover effect the data
of the second period are a true reflection of the first period
because the two treatment groups are symmetrical.
To test the treatment effect (φ) the sum of the results
of treatment 1 is compared with the treatment 2 results
(Yi.i + Y2.2 vs yi.2 + Y2.i). To trace the carryover effect
(λ) the sum of the results in group 1 is compared with
the group 2 results (yL1 + y1-2 vs y2-1 + y2.2). To trace
the time effect (π) the sum of the results in period 1 is
compared with the period 2 results (yi.i + y2.i vs
Yl.2 + Υ2.2>·
The null-hypotheses that φ, λ, and π are zero
Φ [(Υι.ι + Y2.2) - (Yi.2 + Y2.i)l = 0
λ [(Υ2.1 + Y2.2> - (Yl.1 + Υΐ.2>] = 0
π [(Υΐ.Ι + Y2.l) - (Yl.2 + Y2.2>] = 0
should be slightly remodelled into
Ψ [(Yl.l - Yl.2) - (Y2.1 - Y2.2)] = 0
λ [(Υ2.1 + Y2.2> - (Yl.l + Yl.2>] = 0
π [(Yl.l - Yl.2) + (Y2.1 - Y2.2)] = 0
In this way 2 X 2 paired cells can be adequately added
or subtracted in a cell by cell manner.
These null hypotheses can be tested, for example, by t-
statistic or one-way analysis of variance (ANOVA). The
larger the extent to which the t or F value of our distribu-
tion differs from zero, the more sensitivity and power
the statistical approach provides.
d
t = — (or one-way ANOVA, F value)
O.L/
where d is φ, λ, or π, and SE is their standard error.
SE is calculated by use of the standard formulas for the






= σ? + oi +
= σ2 + σ! -
2
^unpaired sums = σ2 + σ!
2 _ _2 ι _2
^unpaired differences ~ σ! """ σ2
We assume that σ = σΥι ι = aYJ 2 = σγ2.ι = σΥ2.2 =
standard deviation of the samples in each of the cells,
and that ρ = ργι.ι Vs γ 1.2 = PY2.i vs Y2.2 = correlation




2 (2α2) (l - p)
2 (2ο2) (1 + p)
2 (2α2) ( l -p)
Because nt = n2 = η we now can calculate the standard
errors (SE) as follows:
8Εφ = 74α2 (l - p) (l/2n + l/2n)
= ^4σ* (l — p)/n
and accordingly
8Ελ = ^/4σ2 (l + p)/n
8Επ = 74α2 (1 - p)/n
Suppose λ = φ and ρ = 0, then Ιχ = Ιφ. In this situa-
tion the powers to test carryover and the treatment effect
are equal.
If λ = φ and ρ > 0 then ίλ < ίφ
If λ = φ and p < Ο then ίλ > ΐφ
Thus, the powers of testing are largely dependent on
the correlation between treatment modalities p. When-
ever ρ > 0 we will have much more power to test
the treatment effect than carryover effect of similar
size. We should add that in practice σΥι.2 may be
somewhat larger than σγι ls because the larger the
data the larger the variances. If, e.g., σγ12 is 10%
larger than σΥι 1? ρ will change from > 0 to > 0.05.
Thus, in this situation the level of positive correlation
required tends to rise.
If the situation allows the assumption that the reference
treatment in the trial is inert, it will not usually cause a
carryover effect, and consequently we will be able to
account for the carryover effect only in the group that
received the active treatment after the inert treatment.
Assuming that treatment 1 is inert then we will have to
account for the carryover effect in group 2 only, and the
appropriate analysis for carryover effect in this situation
therefore becomes
λ (Υ2.2 - Yl.l) = 0
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Standard error (SE) is calculated by use of the formula
for unpaired differences
σ2λ = 2α2
8Ελ = 72α2 (l/n + l/n)
8Ελ
Again, = Οif λ
if λ = φ
if λ = φ and ρ < Ο
φ and ρ
and ρ > Ο
then ΐχ = Ιφ
then Ιλ < t9
then Ιλ > ίφ.
The time effect (π) is considered to influence the data
of the two treatments in a similar way, and its influence
on treatment differences is therefore negligible.



















Under the assumption λ = 0 we have
Φ = (yi.i - Yi.2 ~ !/2π) - (y2.i - y2.2 - !
= Yl.l ~ Yl.2 - Y2.1 + Y2.2
While the estimate of the time or period effect may be
relevant to clinicians its size apparently does not influ-
ence the analysis of the treatment data, and so it does
not have to be taken into account.
Hypothetical Examples, Power Analysis
The power of testing the treatment effect is therefore
heavily dependent on the variances of the paired differ-
ences. This can be illustrated by the example in figure
1. It shows how levels of correlation between two treat-
ment modalities influence the variances of paired differ-
ences in opposite ways. In the case of a negative correla-
tion the standard error of the paired differences largely
outnumbers the standard error of the positive correlation
situation, while the zero-correlation-standard error is in-
between. This is, of course, the main reason that finding
a significant difference between two samples with a pos-
itive correlation is much easier than when the correlation
is negative. Suppose we have 3 crossovers with the data
of figure 1 hi Group 1, and that Group 2 is a true reflec-
tion of Group 1.



























In the given example improvement is measured by the
number of Raynaud attacks/week. Vasodilator 2 is more
efficient than vasodilator 1, because there are fewer at-
tacks. Suppose, this result causes a physical carryover
effect in Group 2 from period 1 into period 2. Then, the
mean value at y2.2 changes from 35 into 35 — λ, where
λ = mean value of carryover effect in Group 2 of the
trial. If, for the purpose of this particular example, we
assume that the variance of λ is zero, it can be simply
subtracted from the paired differences of the groups
without influencing their standard errors. It does not in-
validate the overall conclusions of the procedure, be-
cause any variance larger than zero has to be added to
the variances already in the study, thus further reducing
the power of testing. This assumption therefore produces
the largest powers for the given data. Calculations are
carried out by paired and unpaired t-statistics, and power
is approximated from the equation
POWER = 1 - β = 1 - prob [Z < (t1 - t)]
where Z represents the standardized value for the differ-
ences between two means, t1 represents the upper criti-
cal value of t for the given degrees of freedom, and α
has been specified (treatment effect α = 0.05, carryover








zero correlation positive correlation
10 20 30 40 10 20 30 40 1 20 30 40
Treatment effects of vasodilator 2 [Renaud attacks per week]
Fig. 1 Individual values of paired observations with similar group means, n's and SD's
(vasodilator 1: 35 ± 10, vadodilator 2: 25 ± 10).
negative correlation (p = — 1): SE paired differences 6.8
zero correlation (p = 0): SE paired differences 2.9
positive correlation (p = +1): SE paired differences 0.8
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Mean carryover effect in Group 2
[Raynaud attacks per week]
Fig. 2 Power graphs of tests for treatment effect (slope down-
wards) and carryover effect (slope upwards) of the three crossover
situations from figure 1 with the variable λ (mean carryover effect
in group 2) added.
ρ = -1; Ρ = 0; p s +1
power graphs are drawn of tests for treatment and carry-
over effects of the three crossover situations from figure
1 with the variable λ added. First, there are three power
curves of the treatment effect for the three correlation
situations. As λ increases, all three gradually come
down. The negative correlation curve is the first to do
so. Consequently, this situation has generally little
power of coming to the correct conclusion. At λ = 10,
when the treatment effect is equal to the carryover ef-
fect, there is less than 30% power left. This means that
there is a more than 70% chance that the treatment effect
is erroneously unobserved in this study. Considering that
a power of approximately 80% is required for reliable
testing, we cannot test carryover here in a sensitive man-
ner. The zero and positive correlation situations provide
essentially more power.
There are also three power curves of carryover effect for
the three correlation situations. The negative correlation
curve provides essentially better power than the zero and
positive correlation curves do. This example shows that
strong positive correlations leave little power to test a
carryover effect. It also shows that strong negative cor-
relations produce excessive power to test a carryover ef-
fect.
Figure 3 gives the alternative approach where a carry-
over effect is tested according to the one-group carry-
over principle. In this approach the three different corre-
lation situations have one and the same carryover curve
because the unpaired comparison for carryover has iden-
tical means, standard deviations, and n's, and is there-
fore not influenced by different levels of correlation. It
is actually the same curve as the λ = 0 curve from fig-
ure 2. Its power increases with λ. At λ = 10, when the
treatment effect is equal to the carryover effect, it is
about 80%.
The latter approach should be performed instead of the
former whenever it is permitted by the modalities of
treatment. This is because it both offers less power with
negative correlations and more power with positive cor-
relations. In so doing it prevents the detection of small
and clinically irrelevant carryover effects, and at the
same time the detection of small and clinically unim-
portant treatment effects.
Discussion
Crossover studies are routinely used in clinical research.
For example no less than 22% of the double-blind pla-
cebo-controlled hypertension trials published in 1993
were crossover studies (9, 10). A major advantage of
the crossover design is that it eliminates between-subject
variability of symptoms. However, problems include the
occurrence of carryover and time effects, and the fact
that the design itself offers little power to test such ef-
fects. Power of testing such effects is enhanced by the
use of ANCOVA which is able to test treatment, carry-
over and time effects simultaneously (3—6). ANCOVA
in its current form does not allow, however, for corre-
lations being negative which is an important possibility
in studies comparing completely different treatments.
Adding another covariate to adjust this flaw weakens the
ANCOVA and makes it hardly testable. An alternative
approach is the classic two-stage analysis in which car-
ryover and time effects are tested first and the treatment
effect second. The power of this approach is enhanced








Mean carryover effect in Group 2
(Raynaud attacks per week]
Fig. 3 Power graph of tests for carryover effect of the three cross-
over situations from figure 1 with the variable λ (mean carryover
effect in group 2) added.
The graph displays a carryover effect irrespective of the size of ρ
(one-group carryover effect analysis).
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are analysed in the form of 2 X 2 cells of the same or-
der, which are added or subtracted in a cell by cell man-
ner.
The alternative analysis for crossover studies as pre-
sented in this paper includes the following steps:
1. Carryover and treatment effects in a crossover study
are tested by use of matrix algebra, in which 2 pairs of
cells of the same order are added or subtracted.
2. A one-group analysis for the carryover effect is per-
formed whenever the clinical situation permits it. It gen-
erally offers a more adequate power for testing the data.
3. While the estimate of time effects may be relevant to
clinicians its size does not influence the estimate of the
treatment effects, and, therefore, does not have to be
taken into account in the analysis of the treatment data.
4. In crossover trials with a zero or positive correlation,
small carryover effects hardly reduce the power of dem-
onstrating a treatment effect. Nevertheless, it makes
sense to test for a carryover effect in the group that re-
ceived the effective compound first. If such testing is
positive, a parallel-group analysis of period 1 of the trial
can effectively be used for demonstrating a treatment ef-
fect.
In the event of a significant carryover effect in group
2, a parallel-group analysis of period 1 will provide a
significant test as well, and it will do so at the same or
even at a higher level of significance than the test for a
carryover effect. This is because when the carryover ef-
fect is maximal, the mean response in period 2 group 2,
is that y2.2 equals y2.i. The between-group difference
between y2.i and yL1 in period 1 will, therefore, be at
least as large as the difference between y2.2 and yi ι but
probably larger. Therefore, no further test for a treatment
effect seems to be required in this situation, and the data
of period 2 could be disregarded. If we still wish to
enhance the power of testing this situation, we could
perfectly well make us of the unbiased period-2-data of
group 1 using a weighting procedure (11).
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